Lutein

Phase 3Small molecule

NNational Eye Institute (NEI)

Lutein is one of 94 small molecule programs targeting Retinitis Pigmentosa. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis PigmentosaActive, not recruiting

Oxidative StressActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Retinitis PigmentosaPhase 3

Active, not recruiting

Oxidative StressPhase 1/Phase 2

Active, not recruiting

Age-Related Macular DegenerationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Age2 trials

"Visiobiane Anti-age" Effects on Vision Parameters

Completed·PPiLeJe·Phase 4·NCT00449917·30 enrolled

Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60

Completed·NNational Eye Institute (NEI)·Phase 1·NCT00121589·40 enrolled

Retinitis Pigmentosa2 trials

Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

Completed·NNational Eye Institute (NEI)·Phase 3·NCT00346333·240 enrolled

Effects of Lutein in Retinitis Pigmentosa

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00029289

Age-Related Macular Degeneration2 trials

Lutein for Age-Related Macular Degeneration

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00006202·45 enrolled

Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration

Unknown status·PPeking University·Phase 1/2·NCT01048476·120 enrolled

Oxidative Stress1 trial

Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers

Unknown status·PPeking University·Phase 1/2·NCT01056094·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Lutein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Eye Institute (NEI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Eye Institute (NEI)

Lutein

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Age2 trials

Retinitis Pigmentosa2 trials

Age-Related Macular Degeneration2 trials

Oxidative Stress1 trial

References

Drug Info

Quick Facts

Related News